Cutanos GmbH is a biotech company founded in early 2021 focussing on the development of antigen-specific vaccines and new treatments for autoimmune disorders. Cutanos uses a modular and highly flexible drug delivery system called the Langerhans Cell Targeted Delivery System (LC-TDS). With this technology, the company aims to realize innovative immunotherapies in conjunction with minimally invasive administration. As a spin-off of the Max Planck Institute of Colloids and Interfaces, Cutanos will demonstrate the full range of its platform technology from their headquarter in Austrian capital of Vienna, financed by an equally motivated investment consortium (including KHAN-I, HTGF and IST cube).


HTGF Investment Cutanos

Cutanos Gründerteam
Cutanos closes first financing round with investor consortium from Austria and Germany Max Planck spin-off develops immunotherapies through innovative platform technology Vienna, July 5 2021 – Cutanos GmbH, a Viennese biotech start-up, announces the successful…

Info & Contact

+43 676 576 01 86
Dr. Robert Wawrzinek, Managing Director


Cutanos GmbH
A-1090 Wien, Althanstrasse 14 (UZA II)

In portfolio

23. Apr 2021